RESUMO
Current conventional endoscopes have restricted the accuracy of treatment delivery and monitoring. Over the past decade, there have been major developments in nanotechnology and light triggered therapy, potentially allowing a better detection of challenging lesions and targeted treatment of malignancies in the gastrointestinal tract. Theranostics is a developing form of personalized medicine because it combines diagnosis and targeted treatment delivered in one step using advances in nanotechnology. This review describes the light-triggered therapies (including photodynamic, photothermal, and photoimmunotherapies), nanotechnological advances with nanopowder, nanostent, nanogels, and nanoparticles, enhancements brought to endoscopic ultrasound, in addition to experimental endoscopic techniques, combining both enhanced diagnoses and therapies, including a developed prototype of a "smart" multifunctional endoscope for localized colorectal cancer, near-infrared laser endoscope targeting the gastrointestinal stromal tumors, the concept of endocapsule for obscure gastrointestinal bleed, and a proof-of-concept therapeutic capsule using ultrasound-mediated targeted drug delivery. Hence, the following term has been proposed encompassing these technologies: "Theranostic gastrointestinal endoscopy." Future efforts for integration of these technologies into clinical practice would be directed toward translational and clinical trials translating into a more personalized and interdisciplinary diagnosis and treatment, shorter procedural time, higher precision, higher cost-effectiveness, and less need for repetitive procedures.
Assuntos
Endoscopia Gastrointestinal/métodos , Gastroenteropatias/terapia , Nanoestruturas/administração & dosagem , Fototerapia/métodos , Nanomedicina Teranóstica/métodos , Análise Custo-Benefício , Endoscopia Gastrointestinal/economia , Endoscopia Gastrointestinal/instrumentação , Endossonografia/instrumentação , Endossonografia/métodos , Mucosa Gástrica/diagnóstico por imagem , Mucosa Gástrica/efeitos dos fármacos , Mucosa Gástrica/efeitos da radiação , Gastroenteropatias/diagnóstico , Gastroenteropatias/economia , Humanos , Mucosa Intestinal/diagnóstico por imagem , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/efeitos da radiação , Luz , Fototerapia/economia , Fototerapia/instrumentação , Nanomedicina Teranóstica/economia , Nanomedicina Teranóstica/instrumentaçãoAssuntos
Radioisótopos de Gálio , Revisão da Utilização de Seguros , Seguro Saúde/economia , Tumores Neuroendócrinos/diagnóstico por imagem , Compostos Organometálicos/economia , Centers for Medicare and Medicaid Services, U.S. , Tomada de Decisões , Custos de Cuidados de Saúde , Humanos , Seguro Saúde/legislação & jurisprudência , Imagem Multimodal , Compostos Organometálicos/química , Tomografia por Emissão de Pósitrons , Setor Privado , Nanomedicina Teranóstica/economia , Estados Unidos , United States Food and Drug AdministrationRESUMO
Although use of the term "theranostic" is relatively recent, the concept goes back to the earliest days of nuclear medicine, with the use of radioiodine for diagnosis and therapy of benign and malignant thyroid disease being arguably the most successful molecular radiotherapy in history. A diagnostic scan with 123I-, 124I-, or a low activity of 131I-iodide is followed by therapy with high activity 131I-iodide. Similarly, adrenergic tumours such as phaeochromocytoma and neuroblastoma can be imaged with 123I-metaiodobenzylguanidine and treated with 131I-metaiodobenzylguanidine. Bone scintigraphy can be used to select patients with painful bone metastases from prostate cancer who may benefit from treatment with beta- or alpha-particle emitting bone seeking agents, the most recent and successful of which is 223Ra radium chloride. Anti-CD20 monoclonal antibodies can be used to image and treat non-Hodgkins lymphoma, though this has not been as commercially successful as initially predicted. More recently established theranostics include somatostatin receptor targeting peptides for diagnosis and treatment of neuroendocrine tumours with agents such as 68Ga-DOTATATE and 177Lu-DOTATATE, respectively. Finally, agents which target prostate-specific membrane antigen are becoming increasingly widely available, despite the current lack of a commercial product. With the recent licensing of the somatostatin peptides and the rapid adoption of 68Ga- and 177Lu-labelled prostate-specific membrane antigen targeting agents, we have built upon the experience of radioiodine and are already seeing a great expansion in the availability of widely accepted theranostic radiopharmaceuticals.